Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Smartwatch AI could spot hidden heart condition

NCT ID NCT07291570

Diagnosis Sponsor: Royal Brompton & Harefield NHS Foundation Trust Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jul 16, 2026 · Updated 2 times

Summary

This study will test whether an artificial intelligence (AI) program can accurately detect atrial fibrillation (AF) using data from consumer smartwatches. Researchers will enroll 40 adults with AF who will wear a smartwatch while their heart rhythm is also monitored with standard devices. The goal is to develop a non-invasive, continuous monitoring method that could lead to earlier diagnosis and better management of AF.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
AI algorithm using PPG-derived data from a wearable device
What this could lead to
If successful, this could lead to a non-invasive, continuous way to detect atrial fibrillation early using consumer smartwatches, potentially reducing strokes and hospital visits.
What could go wrong
This is a small, early-stage study with only 40 participants. The AI algorithm may not be accurate enough in real-world settings, and results may not apply to all types of atrial fibrillation.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 40 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jan 2026

Expected to finish

May 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients with confirmed diagnosis of paroxysmal AF or persistent AF who have undergone treatment to restore sinus rhythm

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Adults aged 18 and above with a confirmed diagnosis of paroxysmal AF or those who have undergone treatment for paroxysmal, or persistent AF and had sinus rhythm restored. 2. Capability to provide informed consent, coupled with self-reported sufficiency of digital literacy. 3. Regular access to a Wi-Fi connection (at least weekly). 4. Own a smartphone (released after 2017). Exclusion Criteria: 1. Individuals with permanent or persistent AF that remains uncontrolled despite receiving treatment. 2. Conditions or disabilities that preclude adherence to study instructions or proper use of the devices. 3. A known severe allergy to any of the materials in the wearable or ECG device poses a risk to participant safety.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Atrial fibrillation (AF) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

atrial fibrillation paroxysmal atrial fibrillation persistent atrial fibrillation

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Atrial fibrillation (AF)

Contacts and locations

Locations

  • Royal Brompton and Harefield Hospitals, Guy's and St Thomas' NHS Foundation Trust

    London, London, UB9 6JH, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.